Abstract Details

Title Describing the Population of Patients with Prolonged Seizures: US Subgroup Results from a Global Real-world Point-in-time Study

Topic Epilepsy/Clinical Neurophysiology (EEG)

Presentation(s) P7 - Poster Session 7 (8:00 AM-9:00 AM)

Poster/Presentation
Number 11-001

Objective To describe patient characteristics, treatment usage, healthcare resource utilization (HCRU), and overall disease burden among people with epilepsy (PwE) with prolonged seizures (PS) in the United States (US).

Background PwE can experience PS, which may progress to status epilepticus (SE; seizure[s] lasting ≥5 minutes).

Design/Methods Data for the US subpopulation were drawn from RWE0807 Adelphi’s PS Disease Specific Programme™ (DSP), a real-world, point-in-time study conducted in France, Germany, Italy, Spain, United Kingdom, US, Japan, and China (March 2023–February 2024). Neurologists/epileptologists completed record forms for PwE aged ≥12 years who had received a stable antiseizure medication regimen and experienced ≥1 PS (lasting ≥2 minutes and/or longer than their normal seizures) in the prior 12 months. Data are reported for PwE with ≥1 PS, for both their PS and non-PS (lasting <2 minutes).

Results 55 neurologists and 7 epileptologists completed records for 545 PwE experiencing PS. Median [Q1-Q3] patient age was 39.0 [29.0-50.0] years, 55% male, and 23% had someone responsible for their daily needs. 39% (n=192/497) of PwE with PS had ever experienced SE, and 24% experienced seizure clusters. During the prior 12 months, 27% of PwE had PS that progressed to SE; early ictal events were similarly experienced by PwE for PS (35%) and non-PS (37%) events. Seizure clusters (PS/non-PS: 14%/9%) and injuries (PS/non-PS: 21%/17%) were more commonly experienced by PwE for their PS than non-PS events. During the prior 12 months, a higher proportion of PwE with PS required HCRU for PS than non-PS. 70% of PwE with PS were currently prescribed rescue medication. 67% of PwE with PS had seizure action plans in place for PS.

Conclusions PwE experiencing PS in the US reported encountering progression to status epilepticus and/or seizure clusters, leading to HCRU. Better options for treating prolonged seizures are needed to prevent seizure progression to more severe states.

Authors/Disclosures
Cedric Laloyaux, PhD (UCBMedical Affairs Center of Expertise) PRESENTER	Dr. Laloyaux has received personal compensation for serving as an employee of UCB.
Eugen Trinka	Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial. Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rapport. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. The institution of Eugen Trinka has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Eugen Trinka has received research support from European Union. Eugen Trinka has received publishing royalties from a publication relating to health care.
Matthew Walker, MBBS, PhD, FRCP	Prof. Walker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EpilepsyGtx. The institution of Prof. Walker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Angelini. The institution of Prof. Walker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB pharma. Prof. Walker has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sage. Prof. Walker has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Pfizer. Prof. Walker has stock in EpilepsyGtx. The institution of Prof. Walker has received research support from MRC. The institution of Prof. Walker has received research support from MRC. The institution of Prof. Walker has received research support from Epilepsy Research Institute. The institution of Prof. Walker has received research support from NIHR. Prof. Walker has received intellectual property interests from a discovery or technology relating to health care.
Reetta Kalviainen, MD (University of Kuopio)	No disclosure on file
Sheryl R. Haut, MD (Albert Einstein College of Medicine)	Dr. Haut has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ventus. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbieVe. Dr. Haut has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Iqvia.
John M. Stern, MD, FAAN	Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Pharma. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for SK Life Science. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurelis. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz Pharma. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for LivaNova. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Neurelis. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for LivaNova. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Stern has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Jazz. Dr. Stern has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for SK Life Sciences. Dr. Stern has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Stern has stock in DEARhealth. Dr. Stern has stock in Ceribell. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care. Dr. Stern has received publishing royalties from a publication relating to health care.
Lawrence J. Hirsch, MD, FAAN (Yale University Comprehensive Epilepsy Center)	Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceribell. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for marinus. The institution of Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rapport Therapeutics. Dr. Hirsch has received publishing royalties from a publication relating to health care. Dr. Hirsch has received publishing royalties from a publication relating to health care. Dr. Hirsch has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker; Faculty for Fellows' training course with Neuropace. Dr. Hirsch has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Natus.
Alexander J. Gillespie	Mr. Gillespie has nothing to disclose.
Laura E. Le Brocq	Miss Le Brocq has nothing to disclose.
Olaf Radunz, MSC	Mr. Radunz has received personal compensation for serving as an employee of UCB Pharma GmbH.
Jessica C. Wilson, PhD	Dr. Wilson has received personal compensation for serving as an employee of UCB. Dr. Wilson has stock in UCB.

��ɫ��

��ɫ��